Actively Recruiting
Comprehensive Program for Hereditary Transthyretin Amyloidosis
Led by Hospital de Alta Complejidad en Red · Updated on 2026-03-24
20
Participants Needed
1
Research Sites
160 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The Comprehensive Program for Hereditary Transthyretin Amyloidosis describes a prospective observational study focused on understanding hereditary transthyretin amyloidosis (ATTR), a progressive and potentially fatal condition marked by amyloid fibril deposits impacting multiple organs. The trial aims to characterize patient phenotypes, investigate factors affecting disease progression, and identify minimum criteria for disease onset. Conducted at Néstor Kirchner Hospital, the trial enrolls participants over 18 years old with confirmed pathogenic TTR variants. It includes thorough evaluations such as genetic testing sponsored by pharmaceutical companies, clinical assessments, and diverse diagnostic tests.
CONDITIONS
Official Title
Comprehensive Program for Hereditary Transthyretin Amyloidosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants with a pathogenic variant of the TTR gene (Hereditary Amyloidosis)
You will not qualify if you...
- Wild-type TTR amyloidosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital Cuenca Alta de Cañuelas
Canuelas, Buenos Aires, Argentina, 1814
Actively Recruiting
Research Team
G
Gisela Zanga, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here